Skip to main content
. 2017 Sep 4;1:28. doi: 10.1038/s41698-017-0032-z

Table 4.

Targeted therapies in melanoma

Target gene Alteration Drug type Candidate
BRAF Amplification/mutation BRAF inhibitor Vemurafenib, dabrafenib
MEK Amplification/mutation MEK inhibitor Trametinib, cobimetinib
CTLA-4 Amplification CTLA-4 inhibitor Ipilimumab
PD-1 PD-1 inhibitor Nivolumab, pembrolizumab